Merck To Spend Up To $2.3B In Ablynx Licensing Deal

Law360, New York (February 3, 2014, 6:26 PM EST) -- Belgian biopharmaceutical company Ablynx NV has inked a licensing agreement with Merck & Co. Inc. worth up to €1.7 billion ($2.3 billion) to develop methods for the body to fight cancer by activating the immune system, the companies said Monday.

Under the deal, a Merck subsidiary will pay Ablynx €20 million upfront and up to €10.7 million in research funding during the initial three-year research term of the collaboration. Ablynx can also receive development, regulatory and commercial milestone payments on achieved sales thresholds for a number...
To view the full article, register now.